About

The launch event of the RETHINKING Alzheimer’s disease White Paper, calling for change in Alzheimer’s care, will take place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper is the first of EBC’s “RETHINKING Alzheimer’s disease” project, looking at how to improve the detection, diagnosis, care and monitoring of AD. The White Paper is particularly looking at how to detect and diagnose the disease at an earlier stage (at mild cognitive impairment – MCI – stage) and what new care pathways would need to be implemented to reach out to patients at that stage. With disease modifying treatments targeting patients with MCI potentially coming to market in the near future, it is also important to see how prepared healthcare systems are to provide these new treatments. You can look forward to a keynote speech on the value of an early diagnosis from a patient perspective, a panel discussion featuring experts involved in the RETHINKING Alzheimer’s disease project, a policy panel with key stakeholders at the European Parliament, the European Commission, the World Health Organization and much more. Register now and share your views on how Alzheimer’s care can be improved by completing a short survey, which will be circulated to all registered participants prior to the event. The results of the survey will feed directly in the policy recommendations of the RETHINKING Alzheimer’s disease White Paper, which will be released following the event. Preliminary results will also be shared to allow for exchange on the needed strategies and plans for change in the Alzheimer’s care pathway. Join the discussion and be part of rethinking the way we approach Alzheimer’s disease. All participants must register before attending this event. Zoom instructions will be sent via email once registered.